An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Status:	Recruiting
Conditions:	Prostate Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	1/17/2019
Start Date:	December 15, 2017
End Date:	November 18, 2020
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
Email:	Clinical.Trials@bms.com
Phone:	please email:

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

The purpose of this study is to assess the safety and efficacy of nivolumab in combination
with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate
cancer that has spread.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histologic confirmation of adenocarcinoma of the prostate

- Evidence of stage IV disease on previous bone, CT, and/or MRI scan

- Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone
(GnRH) analogue or bilateral orchiectomy

- Mandatory plasma and fresh or archival tumor tissue must be submitted

Exclusion Criteria:

- Prior malignancy active within the previous 3 years except for locally curable cancers
that have been apparently cured, such as basal or squamous cell skin cancer,
superficial bladder cancer, or carcinoma in situ of the breast

- Participants with active brain metastases

- Participants must have recovered from the effects of major surgery requiring general
anesthesia or significant traumatic injury at least 14 days before treatment arm
assignment

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

New York Oncology Hematology, P.C.

Amsterdam, New York 12010

Phone: 518-262-2767

from

Amsterdam, NY